Rui-Jun Eveline Li

Rui-Jun Eveline Li

Auto-generated profile, based on publicly available information

Rui-Jun Eveline Li

Department of Molecular Cell Biology and Immunology Amsterdam UMC Location Vrije Universiteit Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2019 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
RLRui-Jun Eveline Li
Rui-Jun Eveline Li
THTim P. Hogervorst
Tim P. Hogervorst
SASilvia Achilli
Silvia Achilli
SBSven C. Bruijns
Sven C. Bruijns
TATim Arnoldus
Tim Arnoldus
YKYvette van Kooyk
Yvette van Kooyk
Dendritic cells (DCs) are important initiators of adaptive immunity, and they possess a multitude of Pattern Recognition Receptors (PRR) to generate an adequate T cell mediated immunity against invading pathogens. PRR ligands are frequently conjugated to tumor-associated antigens in a vaccination strategy to enhance the immune response toward such antigens. One of these PPRs, DC-SIGN, a member of the C-type lectin receptor (CLR) family, has been extensively targeted with Lewis structures and mannose glycans, often presented in multivalent fashion. We synthesized a library of well-defined mannosides (mono-, di-, and tri-mannosides), based on known “high mannose” structures, that we presented in a systematically increasing number of copies (n = 1, 2, 3, or 6), allowing us to simultaneously study the effect of mannoside configuration and multivalency on DC-SIGN binding via Surface Plasmon Resonance (SPR) and flow cytometry. Hexavalent presentation of the clusters showed the highest binding affinity, with the hexa-α1,2-di-mannoside being the most potent ligand. The four highest binding hexavalent mannoside structures were conjugated to a model melanoma gp100-peptide antigen and further equipped with a Toll-like receptor 7 (TLR7)-agonist as adjuvant for DC maturation, creating a trifunctional vaccine conjugate. Interestingly, DC-SIGN affinity of the mannoside clusters did not directly correlate with antigen presentation enhancing properties and the α1,2-di-mannoside cluster with the highest binding affinity in our library even hampered T cell activation. Overall, this systematic study has demonstrated that multivalent glycan presentation can improve DC-SIGN binding but enhanced binding cannot be directly translated into enhanced antigen presentation and the sole assessment of binding affinity is thus insufficient to determine further functional biological activity. Furthermore, we show that well-defined antigen conjugates combining two different PRR ligands can be generated in a modular fashion to increase the effectiveness of vaccine constructs.

25 February 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
AZAnouk Zaal
Anouk Zaal
RLR. J. Eveline Li
R. J. Eveline Li
JLJoyce Lübbers
Joyce Lübbers
SBSven C. M. Bruijns
Sven C. M. Bruijns
HKHakan Kalay
Hakan Kalay
Sandra J. Van VlietSandra J. Van Vliet
Sandra J. Van Vliet
Many tumors display alterations in the biosynthetic pathways of glycosylation, resulting in increased expression of specific tumor-associated glycan structures. Expression of these altered glycan structures is associated with metastasis and poor prognosis. Antigen presenting cells can recognize tumor-associated glycan structures, including the truncated O-glycan Tn antigen, via specific glycan receptors. Tn antigen-mediated activation of the C-type lectin MGL on dendritic cells induces regulatory T cells via the enhanced secretion of IL-10. Although these findings indicate that MGL engagement by glycan ligands can modulate immune responses, the impact of MGL ligation on dendritic cells is still not completely understood. Therefore, we employed RNA sequencing, GO term enrichment and pathway analysis on human monocyte-derived dendritic cells stimulated with two different MGL glycan ligands. Our analyses revealed a reduced expression of genes coding for key enzymes involved in the glycolysis pathway, TCA cycle and oxidative phosphorylation. In concordance with this, extracellular flux analysis confirmed the decrease in glycolytic activity upon MGL triggering in human dendritic cells. To our knowledge, we are the first to report a diminished glycolytic activity of human dendritic cells upon C-type lectin stimulation. Overall, our findings highlight the impact of tumor-associated glycans on dendritic cell biology and metabolism and will increase our understanding on how glycans can shape immunity.

11 February 2020 in ACS Chemical Biology
Verified
Journal Article
Open access
THTim P. Hogervorst
Tim P. Hogervorst
RLR. J. Eveline Li
R. J. Eveline Li
LMLaura Marino
Laura Marino
SBSven C. M. Bruijns
Sven C. M. Bruijns
NMNico J. Meeuwenoord
Nico J. Meeuwenoord
JCJeroen Codée
Jeroen Codée
Dendritic cells (DCs) are armed with a multitude of Pattern Recognition Receptors (PRRs) to recognize pathogens and initiate pathogen-tailored T cell responses. In these responses, the maturation of DCs is key, as well as the production of cytokines that help to accomplish T cell responses. DC-SIGN is a frequently exploited PRR that can effectively be targeted with mannosylated antigens to enhance the induction of antigen-specific T cells. The natural O-mannosidic linkage is susceptible to enzymatic degradation, and its chemical sensitivity complicates the synthesis of mannosylated antigens. For this reason, (oligo)mannosides are generally introduced in a late stage of the antigen synthesis, requiring orthogonal conjugation handles for their attachment. To increase the stability of the mannosides and streamline the synthesis of mannosylated peptide antigens, we here describe the development of an acid-stable C-mannosyl lysine, which allows for the inline introduction of mannosides during solid-phase peptide synthesis (SPPS). By substituting the exo-cyclic oxygen with a methylene moiety, the mannosyl linkage is protected against acidic hydrolysis. The developed amino acid has been successfully used for the assembly of both small ligands and peptide antigen conjugates comprising an epitope of the gp100 melanoma-associated antigen and a TLR7 agonist for DC activation. The ligands showed similar internalization capacities and binding affinities as the O-mannosyl analogs. Moreover, the antigen conjugates were capable of inducing maturation, stimulating the secretion of pro-inflammatory cytokines, and providing enhanced gp100 presentation to CD8+ and CD4+ T cells, similar to their O-mannosyl counterparts. Our results demonstrate that the C-mannose lysine is a valuable building block for the generation of anti-cancer peptide-conjugate vaccine modalities.

1 June 2018 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
RLRj Eveline Li
Rj Eveline Li
Sandra J. Van VlietSandra J. Van Vliet
Sandra J. Van Vliet
YKYvette van Kooyk
Yvette van Kooyk

1 December 2019 in Current Opinion in Chemical Biology
Verified
Journal Article
Closed access
SDSanne Duinkerken
Sanne Duinkerken
RLR. Eveline Li
R. Eveline Li
FHFloortje J. van Haften
Floortje J. van Haften
TGTanja D. de Gruijl
Tanja D. de Gruijl
FCFabrizio Chiodo
Fabrizio Chiodo
YKYvette van Kooyk
Yvette van Kooyk

1 December 2015 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
MSMaaike R. Scheenstra
Maaike R. Scheenstra
VSVishal Salunkhe
Vishal Salunkhe
ICIris Maria De Cuyper
Iris Maria De Cuyper
MHMark Hoogenboezem
Mark Hoogenboezem
ELEveline Li
Eveline Li
LGLaura Gutiérrez
Laura Gutiérrez